Sun Pharmaceutical Industries Limited — Investor Meet, 04-02-2026: Analysts/Institutional Investor Meet/Con. Call Updates

Sun Pharma's Q3 FY26: Consolidated sales up 15.1% to Rs 15,469.1 Cr. EBITDA jumped 23.4% to Rs 4,948.5 Cr, with margins at 31.9% on better product mix. Net profit rose 16% to Rs 3,368.8 Cr. Interim dividend declared at Rs 11/share.

Global Innovative Medicines sales increased 14.3% ($423M). India formulations saw 16.2% growth, launching 12 new products & preparing for generic Semaglutide (Noveltreat, Sematrinity). US innovative sales offset generic declines. New launches like Unloxcyt (US) and Ilumya (India) show positive early traction. R&D spend was Rs 892.8 Cr. Management is confident on pipeline, market expansion, and strategic growth initiatives.